Page 1 - reflections_dyslipidaemia_newsletter5_2023
P. 1
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #6 2023
TABLE OF CONTENTS
KEY ARTICLES
EPIDEMIOLOGY Welcome to our next installment of Reflections Dyslipidaemia
Global effect of modifiable risk factors on cardiovascular Global Newsletter, where an international Scientific Planning
disease and mortality. Global Cardiovascular Risk Consortium. Committee summarizes and provides expert commentary
N Engl J Med. 2023 Oct 5;389(14):1273-1285. on the latest clinical and real-world evidence in the field of
Dyslipida
CLINICAL GUIDELINES/STATEMENTS dyslipidaemia. These articles are chosen based on their
2023 ESC Guidelines for the management of acute significance to every day clinical practice. As with the previous
coronary syndromes. Byrne RA, et al. Eur Heart J. 2023 Oct newsletters, we invite you to interact through links to short
12;44(38):3720-3826. video commentaries from our SPC, links to videos, along with
Women, lipids, and atherosclerotic cardiovascular disease: hyperlinks to full articles for in-depth study and reflection. A
A call to action from the European Atherosclerosis Society. new feature in this newsletter is our Conference Corner, where
Roeters van Lennep J, et al. Eur Heart J. 2023 Oct 14;44(39):4157- we highlight some abstracts of interest from the recent 2023
4173. ESC Conference in Amsterdam.
TREATMENT
Prof. Farnier (Chair)
Statin discontinuation after coronary revascularization.
Yamamoto K, et al. Am J Cardiol. 2023 Oct 3:S0002-
9149(23)01029-9. SCIENTIFIC PLANNING COMMITTEE
SPECIAL POPULATIONS
Aggressive LDL-C lowering and the brain: Impact on Prof. Michel Farnier Prof. Augusto Lavalle
risk for dementia and hemorrhagic stroke: A scientific (France) Cobo
statement from the American Heart Association. (Argentina)
Goldstein LB, et al. Arterioscler Thromb Vasc Biol. 2023
Oct;43(10):e404-e442.
Pitavastatin to prevent cardiovascular disease in HIV Prof. Miriam Sandin Prof. Lourdes Santos
infection. Grinspoon SK, et al. N Engl J Med. 2023 Aug (Spain) (Philippines)
24;389(8):687-699.
CONFERENCE CORNER
Highlighted abstracts of interest from the ESC 2023 Prof. Ahmed Shawky Prof. Marcin Welnicki
Conference. (Egypt) (Poland)
ADDITIONAL ARTICLES OF INTEREST
EPIDEMIOLOGY
Global effect of modifiable risk factors on cardiovascular disease and mortality.
Global Cardiovascular Risk Consortium. N Engl J Med. 2023 Oct 5;389(14):1273-1285.
Modifiable risk factors such as body mass index
(BMI), systolic blood pressure (SBP), non-high-density
lipoprotein (non-HDL), cholesterol level, current tobacco
smoking, and diabetes, are thought to increase the risk of
cardiovascular disease and death.
This pooled analysis harmonized individual-level data
from 112 cohort studies conducted in 34 countries and
